By Kate Rawson
"There are FDA wannabes everywhere," John Kamp, executive director of the Coalition for Healthcare Communication declared during The RPM Report’s FDA/CMS Summit in Washington, DC December 4.
Flying Blind: Learning to Live Without Physician Prescribing Data
Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.
More from Legal & IP
More from Pink Sheet
• By
Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.
• By
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
• By
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.